ArticlePharmacology research & perspectives2021

Optimization of dose and route of administration of the P-glycoprotein inhibitor, valspodar (PSC-833) and the P-glycoprotein and breast cancer resistance protein dual-inhibitor, elacridar (GF120918) as dual infusion in rats.

Christopher Rowbottom et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.